Zachary Reardon, MD
Urology · Mobile, ALNPI 1073804209
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 43.1% of the total. Reporting peaked in 2023 at $6,372 and has fallen 83.0% since, to $1,084 in 2025. Among urology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $59.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$8K
- Intuitive Surgical$5K
- Johnson & Johnson$1K
- Astellas Pharma US Inc$802
- Pfizer$673
- Bayer$493
- plus $2K from 34 others
Across 1 payment — averaging $7000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$7K
What the payments were for
- Speaking & faculty fees$6,62535%
- Travel & lodging$7864%
- Food & beverage$6,63635%
- Education$5,04026%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 37 | $8,233 |
| Intuitive Surgical | 8 | $5,419 |
| Johnson & Johnson | 71 | $1,092 |
| Astellas Pharma US Inc | 36 | $802 |
| Pfizer | 39 | $673 |
| Bayer | 21 | $493 |
| Myriad Genetic Laboratories, Inc. | 7 | $299 |
| AstraZeneca | 12 | $215 |
| Novartis | 11 | $177 |
| Sumitomo Pharma America, Inc. | 8 | $138 |
| Urogen Pharma, Inc. | 7 | $123 |
| Procept Biorobotics Corporation | 3 | $123 |
| Blue Earth Diagnostics | 5 | $111 |
| Endo Pharmaceuticals Inc. | 6 | $109 |
| Sun Pharmaceutical Industries Inc. | 4 | $97 |
| Boston Scientific | 5 | $95 |
| Coloplast | 3 | $80 |
| Axonics, Inc. | 2 | $75 |
| Amgen | 4 | $63 |
| Urovant Sciences Inc | 3 | $57 |
| Accord Healthcare, Inc. | 3 | $56 |
| AbbVie | 3 | $47 |
| Merck | 2 | $46 |
| Integra Lifesciences Corporation | 1 | $41 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $39 |
| Progenics Pharmaceuticals, Inc. | 2 | $37 |
| Baxter Healthcare | 2 | $36 |
| Verity Pharmaceuticals Inc. | 2 | $31 |
| Antares Pharma, Inc. | 2 | $31 |
| Medtronic | 1 | $29 |
| Foundation Medicine, Inc. | 2 | $28 |
| ABC Home Medical Supply, Inc. | 1 | $26 |
| Hollister Incorporated | 1 | $26 |
| Endo USA, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $25 |
| Teleflex LLC | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $17 |
| Rochester Medical Corporation | 1 | $16 |
| Myovant Sciences Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$7,533
- DAVINCI XI$3,000
- DA VINCI SP$1,500
- Da Vinci Surgical System$767
- Prolaris$187
- Xofigo$125
- XTANDI$117
How this compares
$19,087 in reported general payments places this provider in the 90th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 506 | $6,718,936 |
| ErleadaApalutamide | 370 | $5,330,475 |
| NubeqaDarolutamide | 159 | $2,129,014 |
| OrgovyxRelugolix | 470 | $1,225,278 |
| Abiraterone Acetate | 124 | $197,378 |
| MyrbetriqMirabegron | 92 | $57,236 |
| GemtesaVibegron | 62 | $48,628 |
| Tamsulosin Hcl | 679 | $10,785 |
| Methenamine Hippurate | 74 | $5,714 |
| Tolterodine Tartrate ErTolterodine Tartrate | 34 | $5,333 |
| Estradiol | 66 | $4,589 |
| Finasteride | 172 | $2,030 |
| Cefdinir | 110 | $1,792 |
| Oxybutynin Chloride ErOxybutynin Chloride | 67 | $1,636 |
| Megestrol Acetate | 48 | $1,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $802 | $6,776,172598 claims |
| Johnson & JohnsonErleada | $1,092 | $5,330,475370 claims |
| BayerNubeqa | $493 | $2,129,014159 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $138 | $1,273,906532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 179 urology providers in Alabama.
Other urology in Mobile
- Lorie FleckMobile$26K
- Ted KleinMobile$18K
- Austin YoungerMobile$18K
- William BlaylockMobile$13K
- Guy OswaltMobile$9K
- Kristie Blanchard-BurchMobile$8K
- Paul ScottMobile$8K
- William SandersonMobile$7K
- Robert HelmMobile$7K
- Thomas ColemanMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.